Literature DB >> 29739774

Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma.

Kosei Matsue1, Hiroki Kobayashi1, Yuya Matsue2, Yoshiaki Abe1, Kentaro Narita1, Akihiro Kitadate1, Masami Takeuchi1.   

Abstract

We aimed to determine the clinical and prognostic significance of medullary abnormalities detected by low-dose whole-body multidetector computed tomography (MDCT) in the appendicular skeleton (AS) of patients with newly diagnosed symptomatic multiple myeloma (MM). One hundred ninety-six patients underwent low-dose whole-body MDCT as an initial workup. Patients were categorized into 3 groups based on the medullary pattern of the AS: fatty (36.3%), focal (43.4%), and diffuse (20.4%). Medullary abnormalities were associated with Durie-Salmon and revised International Scoring System stage 3, creatinine levels >2.0 mg/dL, and the proportion of bone marrow plasma cells. The median follow-up was 35.4 months. Patients with fatty, focal, and diffuse patterns had a median survival of not reached, 56 months, and 38 months, respectively. Overall survival (OS) was associated with age, Durie-Salmon stage 3, creatinine levels >2.0 mg/dL, ineligibility for autologous stem cell transplantation, and focal and diffuse patterns on univariate analysis. Multivariate analysis showed that age and diffuse pattern (hazard ratio [HR], 1.92; 95% confidence interval [CI], 1.12-3.31; P = .018) were independent predictors of progression-free survival. Age and focal (HR, 2.51; 95% CI, 1.14-5.56; P = .023) and diffuse (HR, 4.12; 95% CI, 1.74-9.77; P = .001) patterns were also independent predictors of OS. The addition of marrow pattern to preexisting risk factors was associated with a net reclassification improvement for predicting OS (to 0.37, P = .015). Medullary abnormalities in the AS (detected by low-dose whole-body MDCT) are associated with a poor prognosis, independent of other clinical variables.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29739774      PMCID: PMC5942000          DOI: 10.1182/bloodadvances.2017014720

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  25 in total

1.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

Review 2.  Bone marrow imaging.

Authors:  J B Vogler; W A Murphy
Journal:  Radiology       Date:  1988-09       Impact factor: 11.105

3.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ewout W Steyerberg
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

4.  Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

Authors:  W I Gonsalves; S V Rajkumar; V Gupta; W G Morice; M M Timm; P P Singh; A Dispenzieri; F K Buadi; M Q Lacy; P Kapoor; M A Gertz; S K Kumar
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

5.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

6.  The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.

Authors:  Marius Horger; Lothar Kanz; Barbara Denecke; Reinhard Vonthein; Philippe Pereira; Claus D Claussen; Christoph Driessen
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

7.  Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.

Authors:  M Horger; P Pereira; C D Claussen; L Kanz; R Vonthein; B Denecke; C Driessen
Journal:  Br J Radiol       Date:  2008-05       Impact factor: 3.039

Review 8.  Structural and functional imaging of normal bone marrow and evaluation of its age-related changes.

Authors:  Judy S Blebea; Mohamed Houseni; Drew A Torigian; Chengzhong Fan; Ayse Mavi; Ying Zhuge; Tad Iwanaga; Shipra Mishra; Jay Udupa; Jiyuan Zhuang; Rohit Gopal; Abass Alavi
Journal:  Semin Nucl Med       Date:  2007-05       Impact factor: 4.446

Review 9.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

10.  Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma.

Authors:  Y Nishida; Y Matsue; Y Suehara; K Fukumoto; M Fujisawa; M Takeuchi; E Ouchi; K Matsue
Journal:  Blood Cancer J       Date:  2015-07-31       Impact factor: 11.037

View more
  3 in total

1.  A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.

Authors:  A Paschali; E Panagiotidis; T Triantafyllou; V Palaska; K Tsirou; E Verrou; E Υiannaki; D Markala; A Papanikolaou; A Pouli; P Konstantinidou; V Chatzipavlidou; E Terpos; E Katodritou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-25       Impact factor: 9.236

Review 2.  Progress of modern imaging modalities in multiple myeloma.

Authors:  Toshiki Terao; Kosei Matsue
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.490

3.  MRI-Based Bone Marrow Radiomics Nomogram for Prediction of Overall Survival in Patients With Multiple Myeloma.

Authors:  Yang Li; Yang Liu; Ping Yin; Chuanxi Hao; Chao Sun; Lei Chen; Sicong Wang; Nan Hong
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.